NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Mar 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
LUMIGAN (bimatoprost) by AbbVie is bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. First approved in 2001.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUMIGAN (bimatoprost) is a prostaglandin analog ophthalmic solution approved by the FDA in March 2001 for the treatment of elevated intraocular pressure (IOP) associated with glaucoma and ocular hypertension. The drug works by selectively mimicking prostamides, naturally occurring substances that increase aqueous humor outflow through both the trabecular meshwork and uveoscleral routes. By lowering IOP, a major risk factor for glaucomatous damage and vision loss, bimatoprost helps prevent optic nerve damage and visual field deterioration. It represents a cornerstone therapy in the prostaglandin analog class for first-line and adjunctive glaucoma management.
$0.7BPart D
Mechanism of Action
Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers
Started Feb 2023
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
Started Jun 2022
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
Started Mar 2021
220 enrolled
Open-angle GlaucomaOcular Hypertension
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
Started Jun 2020
37 enrolled
Open-Angle GlaucomaOcular Hypertension
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
Started Mar 2019
455 enrolled
Open-Angle GlaucomaOcular Hypertension
Worked on LUMIGAN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.